Sequencing KRAS-Targeted Therapy in G12C Mutated NSCLC

SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; the gap narrowed at age 80 and older.

Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.

Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.

Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.

Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.

New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.

Phase 3 data at ESMO 2026: sac-TMT and iza-bren beat chemotherapy in NSCLC, while chemo plus pembrolizumab extended PFS in PD-L1–high disease.

ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.